Synergism of Proneurogenic miRNAs Provides a More Effective Strategy to Target Glioma Stem Cells.
Adam KostiRodrigo BarreiroGabriela D A GuardiaShiva OstadrahimiErzsebet KokovayAlexander PertsemlidisPedro A F GalanteLuiz O F PenalvaPublished in: Cancers (2021)
Tumor suppressor microRNAs (miRNAs) have been explored as agents to target cancer stem cells. Most strategies use a single miRNA mimic and present many disadvantages, such as the amount of reagent required and the diluted effect on target genes. miRNAs work in a cooperative fashion to regulate distinct biological processes and pathways. Therefore, we propose that miRNA combinations could provide more efficient ways to target cancer stem cells. We have previously shown that miR-124, miR-128, and miR-137 function synergistically to regulate neurogenesis. We used a combination of these three miRNAs to treat glioma stem cells and showed that this treatment was much more effective than single miRNAs in disrupting cell proliferation and survival and promoting differentiation and response to radiation. Transcriptomic analyses indicated that transcription regulation, angiogenesis, metabolism, and neuronal differentiation are among the main biological processes affected by transfection of this miRNA combination. In conclusion, we demonstrated the value of using combinations of neurogenic miRNAs to disrupt cancer phenotypes and glioma stem cell growth. The synergistic effect of these three miRNA amplified the repression of oncogenic factors and the effect on cancer relevant pathways. Future therapeutic approaches would benefit from utilizing miRNA combinations, especially when targeting cancer-initiating cell populations.
Keyphrases
- cell proliferation
- stem cells
- cancer stem cells
- papillary thyroid
- long non coding rna
- squamous cell
- long noncoding rna
- cell therapy
- cancer therapy
- cell cycle
- transcription factor
- single cell
- lymph node metastasis
- childhood cancer
- radiation therapy
- dna methylation
- spinal cord injury
- pi k akt
- young adults
- genome wide
- drug delivery
- current status
- subarachnoid hemorrhage
- genome wide analysis